TITLE

Pharma: Other News To Note

PUB. DATE
July 2013
SOURCE
BioWorld Today;7/30/2013, Vol. 24 Issue 144, p11
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
This section offers biopharmaceutical sector news briefs including a 10-year agreement between Bristol-Myers Squibb Co. and Samsung Biologics that allows the latter to manufacture a commercial antibody cancer drug for the former, a positive opinion given by the European Committe for Medicinal Products for Human Use to Eisai Inc.'s Zonegran drug for partial seizures, and the move of Pfizer Inc. to separate its operations into three business segments in January 2014.
ACCESSION #
89640919

 

Related Articles

  • CPL Absorbs Bristol-Myers Squibb Facility.  // Pharmaceutical Technology;Oct2005, Vol. 29 Issue 10, p168 

    Reports that Contract Pharmaceuticals Ltd. has purchased a manufacturing facility in Buffalo, New York from Bristol-Myers Squibb Co. Terms of agreement; Benefits from the acquisition.

  • Bristol-Myers Squibb Awards 10-Yr, $550-Mn Outsourcing Contract to Accenture.  // EmergingMarketsNOW;9/12/2008, p10 

    The article focuses on the granting of a 10-year outsourcing contract of Bristol-Myers Squibb Co. to Accenture Ltd. The $550 million contract will allow savings in operational cost and flexibility for Bristol-Myers Squibb Co., a pharmaceutical company. IT and financial support services such as...

  • Bristol-Myers Squibb Awards 10-Yr, $324-Mn HR Contract to IBM.  // EmergingMarketsNOW;6/6/2008, p9 

    The article reports that Bristol-Myers Squibb Co. has awarded a 10-year, $324-million HR support services contract to International Business Machines Corp. (IBM). Through the contract, the U.S.-based pharmaceutical company Bristol-Myers Squibb Co. aims to achieve improved employee experience,...

  • pharma In Brief.  // Chemical Market Reporter;5/24/2004, Vol. 265 Issue 21, p8 

    Presents news briefs pertaining to the pharmaceutical industry in the U.S. as of May 24, 2004, including Biocon Ltd.'s signing of a letter of intent to supply Bristol-Myers Squibb Co. with recombinant human insulin.

  • Bristol-Myers Squibb.  // Formulary;Oct2000 Resource Guide, Vol. 35 Issue 10, p32 

    Features the Bristol-Myers Squibb Co., a pharmaceutical manufacturer. Focus areas of its research and development activities; Best-selling products; Drugs that have received approval from the United States Food and Drug Administration.

  • Bristol-Myers Squibb overhauls management.  // Chemical Market Reporter;11/16/98, Vol. 254 Issue 20, p13 

    Reports on the management reorganization of Bristol-Myers Squibb Co. pharmaceutical company in the United States. Creation of a core management team and three councils to oversee company innovation.

  • The Bristol way. Bustos, Sergio R. // Latin Trade (English);Jan1999, Vol. 7 Issue 1, p26 

    Focuses on United States-based pharmaceutical firm Bristol-Myers Squibb's plan to increase sales in Latin America. Acquisition of local companies; Formation of alliances; Revenues in 1997.

  • Strong profits.  // Crain's New York Business;01/25/99, Vol. 15 Issue 4, p46 

    Announces the profit posted by drug and beauty care products company Bristol-Myers Squibb Co. in the fourth-quarter of 1998.

  • Drugs to Be Sole Focus For Bristol-Myers.  // Mergers & Acquisitions: The Dealermaker's Journal;Jul2001, Vol. 36 Issue 7, p25 

    Reports on Bristol-Myers Squibb Co.'s plans to sell its non-core business units to devote its attention to the pharmaceutical sector. Profitability of the company's non-core units; Bristol-Myers' presence in several business sectors.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics